Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
Sara Tolaney, MD, MPH, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; and senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses sacituzumab govitecan-hziy (Trodelvy) as an effective and safe treatment for patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer.
Despite decades of advances, patients with HR-positive adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancerare in need of new treatment options. However, the FDA recently granted approval to sacituzumab govitecan based on findings from the TROPiCS-02 study (NCT03901339).
According to the final overall survival (OS) analysis of TROPiCS-02, there was a confirmed clinically meaningful OS benefit with sacituzumab govitecan compared with single-agent chemotherapy in this patient population, further supporting the FDA approval. Additionally, this analysis which was presented at ASCO 2023 reinforces the use of sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast and deems it an effective and safe treatment.
Transcription:
0:08 | At ASCO this year, we're presenting the final overall survival analysis from TROPiCS-02. This is a phase 3 trial that compared sacituzumab govitecan with treatment of physicians choice chemotherapy in patients with pretreated metastatic hormone receptor-positive breast cancer. We've previously seen data where we saw that sacituzumab did improve progression-free survival compared with chemotherapy of physicians choice. Then we saw data about overall survival, suggesting that sacituzumab did also improve overall survival compared with treatment of physicians choice.
0:41 | But now at ASCO, we're seeing the final overall survival analysis from this trial. In fact, it continues to show an improvement in progression-free survival and continues to show an improvement in overall survival, going from about 11.2 to 14.5 months. I think [these are] really robust benefits that we're seeing. We also show that these benefits, we are seeing irrespective of TROP2 H-score, as well as irrespective of HER2 IHC score. Benefits are seen across most predefined subgroups.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More